·   Log in

Archive for May 6th, 2010

Dr Reddy’s posts Rs 1.7 billion net profits in Q4 2009-2010; US sales drop

Thursday, May 6, 2010 18:28

India's second largest pharma company Dr Reddy's Laboratories reported a net profit of 1.7 billion rupees ($37 million) in the quarter to March, its fiscal fourth quarter, compared with a loss of 9.8 billion last year.

This was posted under category: Industry  |  Read Full Story  |  0 Comments

Hepatitis c virus could turn resistant against Vertex’ teleprevir

Thursday, May 6, 2010 17:46

Vertex Pharmaceuticals Inc.’s experimental hepatitis C drug telaprevir could become  ineffective as the virus strains turn resistant to the drug.

This was posted under category: health  |  Read Full Story  |  0 Comments
Tagged with: ,

India makes registration of hospitals and clinics compulsory

Thursday, May 6, 2010 17:35

Registration of all clinical establishments made mandatory in India as part of its effort to bring in uniformity in the healthcare delivery sector.

This was posted under category: Featured, health, Legal  |  Read Full Story  |  0 Comments
Tagged with:

Par to market Glenmark’s ezetimibe (Zetia) generic in US

Thursday, May 6, 2010 17:20

Glenmark has entered into an exclusive licensing agreement with Par Pharmaceutical to market ezetimibe 10 mg tablets in US.

This was posted under category: Patents  |  Read Full Story  |  0 Comments

Novartis promotes imatinib (Gleevec) for unapproved dosages to treat gastrointestinal tumours (GIST), myelogenous leukemia (CML): Warns US FDA

Thursday, May 6, 2010 7:58

US FDA has warned Novartis against promoting the use of imatinib (Gleevec) in gastrointestinal stromal tumours (GIST) and chronic myelogenous leukemia (CML) in unapproved dosage strengths.

This was posted under category: Consumer, health  |  Read Full Story  |  0 Comments
Tagged with: ,

Stromal cell-derived factor-1 drug NOX -A12 can treat various cancers: Noxxon

Thursday, May 6, 2010 7:10

NOX-A12, an experimental stromal cell-derived factor-1 to treat various cancers developed  by Noxxon, has successfully completed first-in-man studies, the company announced.

This was posted under category: Biotech  |  Read Full Story  |  0 Comments
Tagged with: ,